Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
¥ 74
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
BrightPath Biotherapeutics Co., Ltd. develops cancer immunotherapy drugs. The company is developing GRN-1201 that is in Phase II clinical study for the treatment of non-small cell lung cancer, as well as in Phase I clinical study to treat melanoma. It also develops BP1101, a neoantigen vaccine; BP1209, a platform of personalized neoantigen cancer vaccines; and...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Data is available to registered users only
Buy
Sell